Normalization of Tumor Vasculature by Imiquimod: Proposal for a New Anticancer Therapeutic Indication for a TLR7 Agonist

Overview

Journal Cancer Immunol Immunother

Date 2025 Feb 1

PMID 39891776

Authors

Jarosz-Biej Magdalena

Czapla Justyna

Ciepla Joanna

Smolarczyk Ryszard

Drzyzga Alina

Sprus-Lipka Dorota

Pilny Ewelina

Matuszczak Sybilla

Cichon Tomasz

Affiliations

Soon will be listed here.

Abstract

Imiquimod (IMQ), a drug from aminoquinoline group, is the toll-like receptor 7 (TLR7) agonist. It acts as an immunostimulant and radio-sensitizing agent. IMQ stimulates both innate and adaptive immune response. Despite studies conducted, there are no unambiguous data showing how IMQ affects the condition of tumor blood vessels. Tumor vasculature plays the main role in tumor progression. Formation of abnormal blood vessels increases area of hypoxia which recruits suppressor cells, blocks tumor infiltration by CD8 T lymphocytes, inhibits efficacy of chemoterapeutic drug and leads to cancer relapse. Normalization is a type of therapy targeted at abnormal tumor blood vessels. Here, we demonstrated that 50 µg of IMQ inhibits the growth of melanoma tumors more efficiently, compared to other tested doses and the control group. Dose escalation did not improve the therapeutic antitumor potential of TLR7 agonist. A dose of 50 µg of IMQ most effectively reduced tumor blood vessel density. Imiquimod normalized tumor vasculature both structurally (by reducing vessel tortuosity and increasing pericyte coverage) and functionally (by improving tumor perfusion) in a dose-dependent manner. Hypoxia regions in tumors of treated mice were significantly reduced after IMQ administration. A dose of 50 µg of IMQ had also the greatest impact on the changes in tumor-infiltrating T lymphocytes levels. TLR7 agonist inhibited angiogenesis in treated mice. Functional vascular normalization by IMQ increases the effectiveness of low dose of doxorubicin. Higher dose of IMQ showed worse effects than lower doses including decreased tumor perfusion, increased tumor hypoxia and immunosuppression. This knowledge may help to optimize the combination of the selected IMQ dose with e.g. chemotherapy or radiotherapy to elicit synergistic effect in cancer treatment. To conclude, we outline IMQ repurposing as a vascular normalizing agent. Our research results may contribute to expanding the therapeutic indications for the use of IMQ in anticancer therapy in the future.

References

Yang T, Xiao H, Liu X, Wang Z, Zhang Q, Wei N . Vascular Normalization: A New Window Opened for Cancer Therapies. Front Oncol. 2021; 11:719836. PMC: 8406857. DOI: 10.3389/fonc.2021.719836. View

Zhao Y, Zhang T, Wang Y, Lu D, Du J, Feng X . ICAM-1 orchestrates the abscopal effect of tumor radiotherapy. Proc Natl Acad Sci U S A. 2021; 118(14). PMC: 8040592. DOI: 10.1073/pnas.2010333118. View

Donin N, Chamie K, Lenis A, Pantuck A, Reddy M, Kivlin D . A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol. 2017; 35(2):39.e1-39.e7. DOI: 10.1016/j.urolonc.2016.09.006. View

Jarosz-Biej M, Kaminska N, Matuszczak S, Cichon T, Pamula-Pilat J, Czapla J . M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma. PLoS One. 2018; 13(1):e0191012. PMC: 5761928. DOI: 10.1371/journal.pone.0191012. View

Ferro M, Crocetto F, Bruzzese D, Imbriaco M, Fusco F, Longo N . Prostate Health Index and Multiparametric MRI: Partners in Crime Fighting Overdiagnosis and Overtreatment in Prostate Cancer. Cancers (Basel). 2021; 13(18). PMC: 8466029. DOI: 10.3390/cancers13184723. View

Magnussen A, Mills I . Vascular normalisation as the stepping stone into tumour microenvironment transformation. Br J Cancer. 2021; 125(3):324-336. PMC: 8329166. DOI: 10.1038/s41416-021-01330-z. View

Liu H, Wen Z, Chen H, Yang Z, Le Z, Liu Z . Nanoadjuvants Actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels. J Control Release. 2022; 352:497-506. DOI: 10.1016/j.jconrel.2022.10.053. View

Choi Y, Jung K . Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med. 2023; 55(11):2308-2319. PMC: 10689787. DOI: 10.1038/s12276-023-01114-w. View

Karashima T, Udaka K, Niimura M, Suzuki K, Osakabe H, Shimamoto T . Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model. Oncol Lett. 2017; 14(1):1162-1166. PMC: 5494610. DOI: 10.3892/ol.2017.6235. View

Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C . HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011; 19(1):31-44. DOI: 10.1016/j.ccr.2010.11.009. View

10.

de Visser K, Joyce J . The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023; 41(3):374-403. DOI: 10.1016/j.ccell.2023.02.016. View

11.

Liotti F, Marotta M, Sorriento D, Pone E, Morra F, Melillo R . Toll-Like Receptor 7 Mediates Inflammation Resolution and Inhibition of Angiogenesis in Non-Small Cell Lung Cancer. Cancers (Basel). 2021; 13(4). PMC: 7916730. DOI: 10.3390/cancers13040740. View

12.

Epah J, Palfi K, Dienst F, Malacarne P, Bremer R, Salamon M . 3D Imaging and Quantitative Analysis of Vascular Networks: A Comparison of Ultramicroscopy and Micro-Computed Tomography. Theranostics. 2018; 8(8):2117-2133. PMC: 5928875. DOI: 10.7150/thno.22610. View

13.

Yang Y, Li H, Fotopoulou C, Cunnea P, Zhao X . Toll-like receptor-targeted anti-tumor therapies: Advances and challenges. Front Immunol. 2022; 13:1049340. PMC: 9721395. DOI: 10.3389/fimmu.2022.1049340. View

14.

Luo X, Zou W, Wei Z, Yu S, Zhao Y, Wu Y . Inducing vascular normalization: A promising strategy for immunotherapy. Int Immunopharmacol. 2022; 112:109167. DOI: 10.1016/j.intimp.2022.109167. View

15.

Smits E, Ponsaerts P, Berneman Z, Van Tendeloo V . The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist. 2008; 13(8):859-75. DOI: 10.1634/theoncologist.2008-0097. View

16.

Kciuk M, Gielecinska A, Mujwar S, Kolat D, Kaluzinska-Kolat Z, Celik I . Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. Cells. 2023; 12(4). PMC: 9954613. DOI: 10.3390/cells12040659. View

17.

Lunardi S, Lim S, Muschel R, Brunner T . IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer. Oncoimmunology. 2015; 4(9):e1027473. PMC: 4570127. DOI: 10.1080/2162402X.2015.1027473. View

18.

Gielecinska A, Kciuk M, Mujwar S, Celik I, Kolat D, Kaluzinska-Kolat Z . Substances of Natural Origin in Medicine: Plants vs. Cancer. Cells. 2023; 12(7). PMC: 10092955. DOI: 10.3390/cells12070986. View

18.

Garcia-Mouronte E, Berna-Rico E, de Nicolas-Ruanes B, Azcarraga-Llobet C, Alonso-Martinez de Salinas L, Bea-Ardebol S . Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer. Int J Mol Sci. 2023; 24(13). PMC: 10341632. DOI: 10.3390/ijms241310835. View